Behavioral Science in Clinical Trials: Part 3 — Why Diversity Must Be Built Into Trial Design
Cannabis clinical trials have historically suffered from poor diversity, limiting generalizability of findings across different populations. Since cannabis response can vary significantly by genetics, metabolism, and social determinants of health, homogeneous trial populations may miss clinically relevant differences in efficacy and safety profiles.
The article discusses integrating behavioral science principles into clinical trial design to improve diversity and representation. For cannabis research, this is particularly relevant given that cannabis use patterns, stigma responses, and therapeutic outcomes can vary substantially across demographic groups. Current cannabis trials often underrepresent minority populations, older adults, and patients with complex comorbidities, potentially limiting the external validity of results for real-world clinical populations.
“I’ve seen firsthand how cannabis response varies dramatically across my patient population — what works for a 25-year-old white male with anxiety may be completely inappropriate for a 65-year-old Black woman with the same condition. We need trials that actually reflect the diversity of patients we treat.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
I notice that the article body you provided appears to be incomplete HTML formatting code without the actual article content. The text cuts off mid-sentence and doesn’t contain the substantive information needed to generate meaningful FAQs.
To create accurate and relevant frequently asked questions, I would need the complete article text that discusses the actual news content, findings, or developments being reported.
Could you please provide the full article content?
